Invitae Prostate Cancer Panel

£595.00

Genetic risk test associated with prostate cancer

This test analyses 19 genes that are associated with increased hereditary risk of developing prostate cancer. It is designed to identify early detection and help guide the right treatment pathway, reduce the risk of reoccurrence and increase the chances of survival.

It is suitable for men who have been diagnosed with inherited germline mutations associated with prostate cancer, or where a hereditary gene mutation has been identified within the family.

Why choose the Invitae Prostate Cancer Panel?

Make vital and informed decisions about the most effective treatment and/or surgery to prevent progression or recurrence.

Identify inherited mutations to ensure that immediate family members are screened from an early age.

Identify pathogenic mutations to prevent progression or recurrence.

Categories: , , , ,
  • More Information

    Prostate cancer is the fifth-most-common malignant cancer in the world. A man’s lifetime risk for developing this type of cancer is 1 in 7 (15%). More than 60% of cases are diagnosed after age 65; it is rarely found in individuals under 40.

    Prostate cancer is currently considered to be a complex, multifactorial disease with the vast majority of familial clustering attributed to the interaction of multiple shared susceptibility genes and environmental factors.

    Inherited pathogenic variants in certain genes, particularly ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PMS2 and TP53 account for some cases of hereditary prostate cancer. Men with pathogenic variants in these genes have an increased risk of developing prostate cancer and, in some cases, other cancers as well.

    Assay information

    This test is developed by Invitae, a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory. The test performs analysis of clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons, depending on the specific gene or test. It also includes the analysis of select non-coding variants.

    Sensitivity

    This assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications.

Description

Genetic risk test associated with prostate cancer

This test analyses 19 genes that are associated with increased hereditary risk of developing prostate cancer. It is designed to identify early detection and help guide the right treatment pathway, reduce the risk of reoccurrence and increase the chances of survival.

It is suitable for men who have been diagnosed with inherited germline mutations associated with prostate cancer, or where a hereditary gene mutation has been identified within the family.

Why choose the Invitae Prostate Cancer Panel?

Make vital and informed decisions about the most effective treatment and/or surgery to prevent progression or recurrence.

Identify inherited mutations to ensure that immediate family members are screened from an early age.

Identify pathogenic mutations to prevent progression or recurrence.

You may also like